TG Therapeutics (NASDAQ:TGTX) Price Target Raised to $43.00

TG Therapeutics (NASDAQ:TGTX - Free Report) had its price objective increased by JPMorgan Chase & Co. from $30.00 to $43.00 in a research note released on Monday,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company's stock.

TGTX has been the subject of several other reports. TD Cowen assumed coverage on TG Therapeutics in a research note on Tuesday, October 29th. They set a "buy" rating and a $50.00 target price for the company. HC Wainwright upped their price objective on TG Therapeutics from $49.00 to $55.00 and gave the stock a "buy" rating in a research report on Tuesday, November 5th. B. Riley lifted their target price on TG Therapeutics from $29.00 to $34.00 and gave the company a "buy" rating in a research report on Wednesday, August 7th. Finally, The Goldman Sachs Group increased their target price on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a "neutral" rating in a report on Tuesday, November 5th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $40.67.

TG Therapeutics Price Performance

Shares of NASDAQ:TGTX traded down $0.46 during trading on Monday, reaching $34.61. 2,865,935 shares of the company traded hands, compared to its average volume of 3,699,043. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. TG Therapeutics has a 52 week low of $12.30 and a 52 week high of $36.84. The firm has a market capitalization of $5.39 billion, a PE ratio of -346.07 and a beta of 2.19. The company's 50 day moving average is $25.81 and its two-hundred day moving average is $21.83.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm had revenue of $83.90 million for the quarter, compared to analyst estimates of $81.68 million. During the same quarter in the previous year, the company earned $0.73 earnings per share. The company's quarterly revenue was down 49.4% on a year-over-year basis. As a group, sell-side analysts predict that TG Therapeutics will post 0.17 earnings per share for the current year.

Insider Activity

In other TG Therapeutics news, Director Sagar Lonial sold 5,000 shares of the company's stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $30.44, for a total value of $152,200.00. Following the sale, the director now owns 100,195 shares in the company, valued at approximately $3,049,935.80. The trade was a 4.75 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 10.50% of the stock is currently owned by insiders.

Institutional Trading of TG Therapeutics

Several institutional investors have recently added to or reduced their stakes in TGTX. NBC Securities Inc. raised its position in shares of TG Therapeutics by 58.9% in the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 485 shares in the last quarter. Quarry LP increased its holdings in TG Therapeutics by 9.1% in the second quarter. Quarry LP now owns 6,003 shares of the biopharmaceutical company's stock worth $107,000 after purchasing an additional 503 shares in the last quarter. Private Advisor Group LLC lifted its stake in TG Therapeutics by 3.9% in the third quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company's stock valued at $337,000 after buying an additional 542 shares during the period. Blue Trust Inc. boosted its holdings in shares of TG Therapeutics by 127.3% during the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company's stock worth $35,000 after buying an additional 849 shares in the last quarter. Finally, KBC Group NV grew its position in shares of TG Therapeutics by 30.5% during the 3rd quarter. KBC Group NV now owns 4,675 shares of the biopharmaceutical company's stock worth $109,000 after buying an additional 1,092 shares during the period. 58.58% of the stock is currently owned by institutional investors.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.